| pubmed-article:16260029 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16260029 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:16260029 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:16260029 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:16260029 | lifeskim:mentions | umls-concept:C0532362 | lld:lifeskim |
| pubmed-article:16260029 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16260029 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16260029 | pubmed:dateCreated | 2006-2-28 | lld:pubmed |
| pubmed-article:16260029 | pubmed:abstractText | To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy. | lld:pubmed |
| pubmed-article:16260029 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16260029 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16260029 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16260029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16260029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16260029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16260029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16260029 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16260029 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:16260029 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:ReedEddieE | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:SeidenMichael... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:GordonAlan... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:BodurkaDiane... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:PensonRichard... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:CullenMichael... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:McGuireWillia... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:MatulonisUrsu... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:AlbertsDave... | lld:pubmed |
| pubmed-article:16260029 | pubmed:author | pubmed-author:WeemsGarryG | lld:pubmed |
| pubmed-article:16260029 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16260029 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:16260029 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16260029 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16260029 | pubmed:pagination | 55-61 | lld:pubmed |
| pubmed-article:16260029 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:meshHeading | pubmed-meshheading:16260029... | lld:pubmed |
| pubmed-article:16260029 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16260029 | pubmed:articleTitle | A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. | lld:pubmed |
| pubmed-article:16260029 | pubmed:affiliation | Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care Program, Boston, MA 02115, USA. mseiden@partners.org | lld:pubmed |
| pubmed-article:16260029 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16260029 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16260029 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:16260029 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
